Foresight regarding drug candidates acting on the succinate–GPR91 signalling pathway for non-alcoholic steatohepatitis (NASH) treatment

Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease, and it is a liver manifestation of metabolic syndrome, with a histological spectrum from simple steatosis to non-alcoholic steatohepatitis (NASH). NASH can evolve into progressive liver fibrosis and eventually lead t...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Chengyuan Liang, Juan Li, Bin Tian, Lei Tian, Yuzhi Liu, Jingyi Li, Liang Xin, Jun Wang, Chao Fu, Zhenfeng Shi, Juan Xia, Yiting Liang, Kun Wang
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Non-alcoholic steatohepatitis (NASH) Non-alcoholic fatty liver disease (NAFLD) Succinate–GPR91 Liver fibrosis Hepatic stellate cells (HSCs) Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/42782507ca174da88ab367632b871d41
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:42782507ca174da88ab367632b871d41
record_format	dspace
spelling	oai:doaj.org-article:42782507ca174da88ab367632b871d412021-11-14T04:29:22ZForesight regarding drug candidates acting on the succinate–GPR91 signalling pathway for non-alcoholic steatohepatitis (NASH) treatment0753-332210.1016/j.biopha.2021.112298https://doaj.org/article/42782507ca174da88ab367632b871d412021-12-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S0753332221010829https://doaj.org/toc/0753-3322Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease, and it is a liver manifestation of metabolic syndrome, with a histological spectrum from simple steatosis to non-alcoholic steatohepatitis (NASH). NASH can evolve into progressive liver fibrosis and eventually lead to liver cirrhosis. The pathological mechanism of NASH is multifactorial, involving a series of metabolic disorders and changes that trigger low-level inflammation in the liver and other organs. In the pathogenesis of NASH, the signal transduction pathway involving succinate and the succinate receptor (G-protein-coupled receptor 91, GPR91) regulates inflammatory cell activation and liver fibrosis. This review describes the mechanism of the succinate–GPR91 signalling pathway in NASH and summarizes the drugs that act on this pathway, with the aim of providing a new approach to NASH treatment.Chengyuan LiangJuan LiBin TianLei TianYuzhi LiuJingyi LiLiang XinJun WangChao FuZhenfeng ShiJuan XiaYiting LiangKun WangElsevierarticleNon-alcoholic steatohepatitis (NASH)Non-alcoholic fatty liver disease (NAFLD)Succinate–GPR91Liver fibrosisHepatic stellate cells (HSCs)Therapeutics. PharmacologyRM1-950ENBiomedicine & Pharmacotherapy, Vol 144, Iss , Pp 112298- (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Non-alcoholic steatohepatitis (NASH) Non-alcoholic fatty liver disease (NAFLD) Succinate–GPR91 Liver fibrosis Hepatic stellate cells (HSCs) Therapeutics. Pharmacology RM1-950
spellingShingle	Non-alcoholic steatohepatitis (NASH) Non-alcoholic fatty liver disease (NAFLD) Succinate–GPR91 Liver fibrosis Hepatic stellate cells (HSCs) Therapeutics. Pharmacology RM1-950 Chengyuan Liang Juan Li Bin Tian Lei Tian Yuzhi Liu Jingyi Li Liang Xin Jun Wang Chao Fu Zhenfeng Shi Juan Xia Yiting Liang Kun Wang Foresight regarding drug candidates acting on the succinate–GPR91 signalling pathway for non-alcoholic steatohepatitis (NASH) treatment
description	Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease, and it is a liver manifestation of metabolic syndrome, with a histological spectrum from simple steatosis to non-alcoholic steatohepatitis (NASH). NASH can evolve into progressive liver fibrosis and eventually lead to liver cirrhosis. The pathological mechanism of NASH is multifactorial, involving a series of metabolic disorders and changes that trigger low-level inflammation in the liver and other organs. In the pathogenesis of NASH, the signal transduction pathway involving succinate and the succinate receptor (G-protein-coupled receptor 91, GPR91) regulates inflammatory cell activation and liver fibrosis. This review describes the mechanism of the succinate–GPR91 signalling pathway in NASH and summarizes the drugs that act on this pathway, with the aim of providing a new approach to NASH treatment.
format	article
author	Chengyuan Liang Juan Li Bin Tian Lei Tian Yuzhi Liu Jingyi Li Liang Xin Jun Wang Chao Fu Zhenfeng Shi Juan Xia Yiting Liang Kun Wang
author_facet	Chengyuan Liang Juan Li Bin Tian Lei Tian Yuzhi Liu Jingyi Li Liang Xin Jun Wang Chao Fu Zhenfeng Shi Juan Xia Yiting Liang Kun Wang
author_sort	Chengyuan Liang
title	Foresight regarding drug candidates acting on the succinate–GPR91 signalling pathway for non-alcoholic steatohepatitis (NASH) treatment
title_short	Foresight regarding drug candidates acting on the succinate–GPR91 signalling pathway for non-alcoholic steatohepatitis (NASH) treatment
title_full	Foresight regarding drug candidates acting on the succinate–GPR91 signalling pathway for non-alcoholic steatohepatitis (NASH) treatment
title_fullStr	Foresight regarding drug candidates acting on the succinate–GPR91 signalling pathway for non-alcoholic steatohepatitis (NASH) treatment
title_full_unstemmed	Foresight regarding drug candidates acting on the succinate–GPR91 signalling pathway for non-alcoholic steatohepatitis (NASH) treatment
title_sort	foresight regarding drug candidates acting on the succinate–gpr91 signalling pathway for non-alcoholic steatohepatitis (nash) treatment
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/42782507ca174da88ab367632b871d41
work_keys_str_mv	AT chengyuanliang foresightregardingdrugcandidatesactingonthesuccinategpr91signallingpathwayfornonalcoholicsteatohepatitisnashtreatment AT juanli foresightregardingdrugcandidatesactingonthesuccinategpr91signallingpathwayfornonalcoholicsteatohepatitisnashtreatment AT bintian foresightregardingdrugcandidatesactingonthesuccinategpr91signallingpathwayfornonalcoholicsteatohepatitisnashtreatment AT leitian foresightregardingdrugcandidatesactingonthesuccinategpr91signallingpathwayfornonalcoholicsteatohepatitisnashtreatment AT yuzhiliu foresightregardingdrugcandidatesactingonthesuccinategpr91signallingpathwayfornonalcoholicsteatohepatitisnashtreatment AT jingyili foresightregardingdrugcandidatesactingonthesuccinategpr91signallingpathwayfornonalcoholicsteatohepatitisnashtreatment AT liangxin foresightregardingdrugcandidatesactingonthesuccinategpr91signallingpathwayfornonalcoholicsteatohepatitisnashtreatment AT junwang foresightregardingdrugcandidatesactingonthesuccinategpr91signallingpathwayfornonalcoholicsteatohepatitisnashtreatment AT chaofu foresightregardingdrugcandidatesactingonthesuccinategpr91signallingpathwayfornonalcoholicsteatohepatitisnashtreatment AT zhenfengshi foresightregardingdrugcandidatesactingonthesuccinategpr91signallingpathwayfornonalcoholicsteatohepatitisnashtreatment AT juanxia foresightregardingdrugcandidatesactingonthesuccinategpr91signallingpathwayfornonalcoholicsteatohepatitisnashtreatment AT yitingliang foresightregardingdrugcandidatesactingonthesuccinategpr91signallingpathwayfornonalcoholicsteatohepatitisnashtreatment AT kunwang foresightregardingdrugcandidatesactingonthesuccinategpr91signallingpathwayfornonalcoholicsteatohepatitisnashtreatment
_version_	1718430008787075072

Foresight regarding drug candidates acting on the succinate–GPR91 signalling pathway for non-alcoholic steatohepatitis (NASH) treatment

Ejemplares similares